In this study, our research showed that the high expression of TFRC has been associated with tumor-infiltrating lymphocyte (TIL) levels (CD8 + T cell, Macrophage cell) and immune checkpoints, suggesting a novel immunotherapy target. The gene discussed is CD8A; the disease is neoplasm.